Abstract:AGel amyloidosis, formerly known as familial amyloidosis of the Finnish-type, is caused by pathological aggregation of proteolytic fragments of plasma gelsolin. So far, four mutations in the gelsolin gene have been reported as responsible for the disease. Although D187N is the first identified variant and the best characterized, its structure has been hitherto elusive. Exploiting a recently-developed nanobody targeting gelsolin, we were able to stabilize the G2 domain of the D187N protein and obtained, for the first time, its high-resolution crystal structure. In the nanobody-stabilized conformation, the main effect of the D187N substitution is the impairment of the calcium binding capability, leading to a destabilization of the C-terminal tail of G2. However, molecular dynamics simulations show that in the absence of the nanobody, D187N-mutated G2 further misfolds, ultimately exposing its hydrophobic core and the furin cleavage site. The nanobody's protective effect is based on the enhancement of the thermodynamic stability of different G2 mutants (D187N, G167R and N184K). In particular, the nanobody reduces the flexibility of dynamic stretches, and most notably decreases the conformational entropy of the C-terminal tail, otherwise stabilized by the presence of the Ca2+ ion. A Caenorhabditis elegans-based assay was also applied to quantify the proteotoxic potential of the mutants and determine whether nanobody stabilization translates into a biologically relevant effect. Successful protection from G2 toxicity in vivo points to the use of C. elegans as a tool for investigating the mechanisms underlying AGel amyloidosis and rapidly screen new therapeutics.

Deciphering the crystal structure of a novel nanobody against the NEIL1 DNA glycosylase

Deciphering the orthorhombic crystal structure of a novel NEIL1 nanobody with pseudo-merohedral twinning

Characterization of a nanobody-epitope tag interaction and its application for receptor engineering

Fab Crystallization and Preliminary X-ray Analysis of NC-1, an Anti-Hiv-1 Antibody That Recognizes the Six-Helix Bundle Core of Gp41.

Gluebodies improve crystal reliability and diversity through transferable nanobody mutations that introduce constitutive close contacts

Structural insights into the binding of nanobody Rh57 to active RhoA-GTP

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo

Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking

Caught in motion: human NTHL1 undergoes interdomain rearrangement necessary for catalysis

Antigen-binding fragments with improved crystal lattice packing and enhanced conformational flexibility at the elbow region as crystallization chaperones

Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture

Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA

Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope

(NZ)CH...O Contacts assist crystallization of a ParB-like nuclease

Crystal Structure of the Neuropilin-1 MAM Domain: Completing the Neuropilin-1 Ectodomain Picture

Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity

Comparative analysis of nanobody sequence and structure data

Cavin1 binding nanobodies reveal structural flexibility and regulated interactions of the N-terminal coiled-coil domain

Structural landscape of engineered multivalent antibody fragments and their application as crystallization scaffolds

Megabodies expand the nanobody toolkit for protein structure determination by single-particle cryo-EM

Nanobody interaction unveils structure, dynamics and proteotoxicity of the Finnish-type amyloidogenic gelsolin variant